C17H 21 BrN 2 S, orthorhombic, Pbca (No. 61), a = 17.0675(7) Å,
Source of material
To a solution of 1-adamantylamine (1.51 g, 0.01 mol) in ethanol (15 mL), 4-bromophenyl isothiocyanate (2.14 g, 0.01 mol) was added and the mixture was heated under re ux for three hours. On cooling, the precipitated crude product was ltered, dried and crystallized from ethanol to yield 3.36 g (92%) of the title compound (C17H 21 . 
Experimental details
Carbon-bound H atoms were placed in calculated positions and were included in the re nement in the riding model approximation, with U iso (H) set to 1.2Ueq(C). The nitrogenbound H atom was located on a di erence Fourier map and re ned freely.
Discussion
The adamantanyl moiety represents the major pharmacophore of various drugs as amantadine [1] [2] [3] , rimantadine [4, 5] and tromantadine [6] , which are currently described as e cient antiviral therapies. Moreover, several adamantanebased drugs are currently employed as important medications against malaria infections [7] , central nervous disorders [8] [9] [10] , hyperglycaemia [11] and drug-resistant TB strain infections [12] . In addition, thiourea derivatives were reported to display marked antitumor [13] , anti-HIV [14] , antimalarial [15] and antimicrobial [16] activities. As a part of our current research interest in the pharmacological [17] [18] [19] and structural [20] [21] [22] properties of adamantane derivatives, we report herein the synthesis and crystal structure of the title compound as bioactive agent and as precursor for adamantanebased chemotherapeutic agents. The asymmetric unit of the title structure contains one independent molecule. All bond lengths and angles of this molecule are in the expected ranges. The molecules packed in the crystal structure via two intermolecular strong classical hydrogen bonds, N1-H1N1· · · S1
i and N2-H1N2· · · S1 i .
The H· · · A distances are 2.602 (18) 
